Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive an ...
(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...
AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at ...
Carla Harris has been diagnosed with and beaten acute myeloid leukemia thanks to a bone marrow transplant from her sister, ...
A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...
A 14-year-old Marshfield freshman was surprised earlier today when a special guest visited the Children’s Mercy Hospital, ...
A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end ...
Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from ...
Study reveals how socioeconomic factors create barriers to bone marrow transplants for AML patients in disadvantaged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback